Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695856 | 1.00 | NR1H2 (0.46) | NR1H2LMNATSHRRIPK1ALOX5AP | |
| SCHEMBL17041234 | 0.88 | RIPK1 (0.50) | LMNATSHRRIPK1NPSR1MAPT | |
| SCHEMBL5206161 | 0.88 | NR1H2 (0.42) | NR1H2LMNATSHRRIPK1ALOX5AP | |
| SCHEMBL25594973 | 0.87 | LMNA (0.48) | NR1H2LMNATSHRNPSR1MAPT | |
| SCHEMBL25599989 | 0.86 | NR1H2 (0.45) | NR1H2LMNATSHRALOX5APFEN1 | |
| SCHEMBL26987927 | 0.86 | USP30 (0.47) | NR1H2LMNATSHRRIPK1NPSR1 | |
| SCHEMBL31413078 | 0.86 | ALDH1A1 (0.52) | LMNATSHRRIPK1NPSR1MAPT | |
| SCHEMBL31290628 | 0.86 | USP30 (0.47) | NR1H2LMNATSHRRIPK1NPSR1 | |
| SCHEMBL16891482 | 0.84 | LMNA (0.45) | LMNATSHRRIPK1ALOX5APFEN1 | |
| SCHEMBL4564195 | 0.81 | RIPK1 (0.48) | LMNATSHRRIPK1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| EP-2328889-A1 | ACETYL PYRROLIDINYL INDOLE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| WO-2010018800-A1 | ACETYL PYRROLIDINYL INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | NR1H2 847/4885LMNA 3434/4885TSHR 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.